Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andrea Burgalassi
Observed name:
Burgalassi, Andrea
Institutions:
Azienda Ospedaliero-Universitaria Careggi,
University of Florence
Observed institutions:
Azienda Ospedaliero-Universitaria Careggi,
University of Florence
ORCID:
0009-0001-7028-7735
Observed ORCID:
0009-0001-7028-7735
OpenAlex ID:
A5077278399
Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study
2023
·
Luigi Francesco Iannone
, Andrea Burgalassi
, et al.
·
Cephalalgia
·
43
Pharmacological differences and switching among anti‐ CGRP monoclonal antibodies: A narrative review
2025
·
Marina Romozzi
, Antonio Munafò
, et al.
·
Headache The Journal of Head and Face Pain
·
38
PDF
Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug–drug interactions
2020
·
Giada Crescioli
, Valentina Brilli
, et al.
·
Internal and Emergency Medicine
·
33
PDF
Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study)
2025
·
Luigi Francesco Iannone
, Gloria Vaghi
, et al.
·
The Journal of Headache and Pain
·
26
PDF
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study
2023
·
Valeria Caponnetto
, Antonio Russo
, et al.
·
CNS Drugs
·
24
PDF
An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine
2024
·
Marina Romozzi
, Ammar Lokhandwala
, et al.
·
Cephalalgia
·
19
Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study
2024
·
Andrea Burgalassi
, Marina Romozzi
, et al.
·
Cephalalgia
·
14
Sex differences in the clinical features of 2,841 patients with migraine: a post-hoc, multicenter, cross-sectional study
2025
·
Marina Romozzi
, Luigi Francesco Iannone
, et al.
·
Frontiers in Neurology
·
10
PDF
Prospective evaluation of aura during anti-calcitonin gene-related peptide monoclonal antibody therapy after 52 weeks of treatment
2024
·
Marina Romozzi
, Andrea Burgalassi
, et al.
·
Confinia Cephalalgica
·
10
Exploring the multifaceted characteristics of aura in migraine: A multicenter, cross-sectional study
2024
·
Giorgio Dalla Volta
, Antonio Russo
, et al.
·
Cephalalgia
·
8
Impact of duration of chronic migraine on long‐term effectiveness of monoclonal antibodies targeting the calcitonin gene‐related peptide pathway—A real‐world study
2024
·
Raffaele Ornello
, Francesca Baldini
, et al.
·
Headache The Journal of Head and Face Pain
·
7
PDF
Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ)
2023
·
Agnese Onofri
, Luigi Francesco Iannone
, et al.
·
Neurological Sciences
·
7
PDF
Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study)
2025
·
Gloria Vaghi
, Luigi Francesco Iannone
, et al.
·
Therapeutic Advances in Neurological Disorders
·
5
Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies
2026
·
Lanfranco Pellesi
, Damiana Scuteri
, et al.
·
Expert Opinion on Emerging Drugs
·
3
Rimegepant as an acute treatment in a refractory migraine patient non-responder to two anti-CGRP monoclonal antibodies and triptans: Case report and pharmacological considerations
2024
·
Andrea Burgalassi
, Giulia Vigani
, et al.
·
Cephalalgia Reports
·
3
Sex and gender differences in the epidemiology, clinical features, and pathophysiology of trigeminal autonomic cephalalgias
2024
·
Selene Attorre
, Andrea Burgalassi
, et al.
·
Confinia Cephalalgica
·
2
Tumor expression of CGRP confers sensitivity to growth inhibition by the anti-CGRP antibody fremanezumab
2026
·
Daniela Buonvicino
, Alessandra Pistolesi
, et al.
·
European Journal of Pharmacology
·
1
PDF
To feed or to fast? Nutritional triggers in migraine: a narrative review
2026
·
Daniele Pala
, Federico Tosto
, et al.
·
Confinia Cephalalgica
·
1
PDF
Effectiveness and safety of lasmiditan and rimegepant in the acute migraine treatment: an indirect real-world comparison
2026
·
Gloria Vaghi
, Luigi Francesco Iannone
, et al.
·
Neurological Sciences
PDF
Preliminary evidence of long‐term safety and effectiveness of anti‐ CGRP drugs for migraine prevention in people with comorbid epilepsy: A 52‐week follow‐up retrospective study
2026
·
Marina Romozzi
, Andrea Burgalassi
, et al.
·
Epilepsia Open
PDF
Migraine in Older Adults: Age‐Related Clinical Features From the Italian RICe Registry
2026
·
Giulia Paparella
, Luigi Francesco Iannone
, et al.
·
European Journal of Neurology
PDF
Effectiveness of rimegepant across multiple acute migraine attacks: A real-world, prospective, multicentric study
2026
·
Gloria Vaghi
, Raffaele Ornello
, et al.
·
Cephalalgia
Beyond symptom: Exploring the analgesic properties of vomiting in patients with migraine
2026
·
Antonio Munafò
, Andrea Burgalassi
, et al.
·
Headache The Journal of Head and Face Pain
PDF
Galcanezumab-associated interstitial pneumonia in a migraine patient: A case report
2026
·
Antonio Munafò
, Alessandro Libra
, et al.
·
Cephalalgia Reports
Cluster Headache Impact Questionnaire--Italian Version
2023
·
Agnese Onofri
, Italian Headache Registry (RICe) Study Group
, et al.
·
PsycTESTS Dataset
Show more works
View as search
Works count:
27
Citation count:
254
H-index:
9
I10-index:
9
Year
Topic
Type